Literature DB >> 22390946

Impact of 5-HT₃ receptor antagonists on peripheral and central diseases.

Gohar Fakhfouri1, Reza Rahimian, Jean-Eric Ghia, Waliul I Khan, Ahmad R Dehpour.   

Abstract

In this article we discuss the novel pharmacological aspects of 5-HT(3) receptor antagonists. Commonly used to counteract chemotherapy-induced emesis, these agents now appear to be reaching out for newer indications. Studies have reported neuroprotective and anti-inflammatory properties in vitro and in vivo. 5-HT(3) receptor antagonists can modulate the immune-inflammatory axis through blockade of 5-HT(3) receptors present on immune cells. We review evidence addressing the effects of these drugs on peripheral inflammatory diseases, including asthma, rheumatoid diseases, inflammatory bowel disease and sepsis in addition to diabetes and CNS disorders, including Alzheimer's disease (AD), seizure and stroke.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22390946     DOI: 10.1016/j.drudis.2012.02.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.

Authors:  Gohar Fakhfouri; Kazem Mousavizadeh; Sharam Ejtemaei Mehr; Ahmad Reza Dehpour; Mohammad Reza Zirak; Jean-Eric Ghia; Reza Rahimian
Journal:  Mol Neurobiol       Date:  2014-11-07       Impact factor: 5.590

Review 2.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

Review 3.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

4.  The Role of Hippocampal 5HT3 Receptors in Harmaline-Induced Memory Deficit.

Authors:  Mohammad Nasehi
Journal:  Basic Clin Neurosci       Date:  2015-07

5.  Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates.

Authors:  Francisco J Romero Durán; Nerea Alonso; Olga Caamaño; Xerardo García-Mera; Matilde Yañez; Francisco J Prado-Prado; Humberto González-Díaz
Journal:  Int J Mol Sci       Date:  2014-09-24       Impact factor: 5.923

Review 6.  The serotonergic system and cognitive function.

Authors:  Dubravka Švob Štrac; Nela Pivac; Dorotea Mück-Šeler
Journal:  Transl Neurosci       Date:  2016-05-09       Impact factor: 1.757

Review 7.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

Review 8.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

9.  The anticonvulsant effects of SR 57227 on pentylenetetrazole-induced seizure in mice.

Authors:  Bingjin Li; Liang Wang; Zhihui Sun; Yang Zhou; Dongyuan Shao; Jing Zhao; Yunong Song; Jiayin Lv; Xue Dong; Changhong Liu; Pu Wang; Xingyi Zhang; Ranji Cui
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

10.  Reduced Mortality With Ondansetron Use in SARS-CoV-2-Infected Inpatients.

Authors:  Vafa Bayat; Russell Ryono; Steven Phelps; Eugene Geis; Farshid Sedghi; Payam Etminani; Mark Holodniy
Journal:  Open Forum Infect Dis       Date:  2021-07-14       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.